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Abstract
Human papilloma virus (HPV) infection is a major risk factor for a distinct
subset of head and neck squamous cell carcinoma (HNSCC). The current
review summarizes the epidemiology of HNSCC and the disease burden, the
infectious cycle of HPV, the roles of viral oncoproteins, E6 and E7, and the
downstream cellular events that lead to malignant transformation. Current
techniques for the clinical diagnosis of HPV-associated HNSCC will also be dis-
cussed, that is, the detection of HPV DNA, RNA, and the HPV surrogate mar-
ker, p16 in tumor tissues, as well as HPV-specific antibodies in serum. Such
methods do not allow for the early detection of HPV-associated HNSCC and
most cases are at an advanced stage upon diagnosis. Novel noninvasive
approaches using oral fluid, a clinically relevant biological fluid, allow for the
detection of HPV and cellular alterations in infected cells, which may aid in the
early detection and HPV-typing of HNSCC tumors. Noninvasive diagnostic
methods will enable early detection and intervention, leading to a significant
reduction in mortality and morbidity associated with HNSCC.
Introduction
Head and neck squamous cell carcinoma (HNSCC)
includes malignancies in five major anatomic sites,
namely, oral cavity, oropharynx, nasopharynx, hypophar-
ynx, and larynx. HNSCC is the sixth most common
malignancy with an estimated annual incidence of
~633,000 and 355,000 deaths worldwide [1]. HNSCCs are
highly curable if detected early and the most common treat-
ments include surgery, radiation therapy, chemotherapy,
or combinations of these three treatments. In the initial
stages of the disease, a patient may not show any clinical
symptoms and as such a significant number of patients
present with metastatic disease at the time of diagnosis
(regional nodal involvement in 43% and distant metasta-
sis in 10%), leading to 5-year survival rates of less than
60% [2].
Oral squamous cell carcinoma (OSCC) and oropha-
ryngeal squamous cell carcinoma (OPSCC) are the most
common types of HNSCC, accounting for 263,900 new
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cases and 128,000 deaths worldwide in 2008 [3].
Tobacco smoking is a major risk factor for HNSCC
with ~80% of cases attributed to tobacco exposure [4].
Alcohol consumption is also a risk factor for HNSCC
[5], which can act synergistically with tobacco to
increase the risk of HNSCC [6]. In recent decades, the
overall incidence of HNSCC is in the decline in the
developed world due to a reduction in the consumption
of tobacco. However, there is a concomitant increase in
the incidence of OPSCC as a result of human papilloma
virus (HPV) infection. Unlike tobacco-related HNSCC,
patients with HPV-associated OPSCC are usually less
likely to have any history of excess tobacco or alcohol
consumption. Instead, about 60% of OPSCC patients in
the western world are positive for the oncogenic forms
of HPV, in particular the 16 subtypes [7]. It is esti-
mated that tumors in the oropharynx are five times
more likely to be HPV-positive than those in the oral
cavity, larynx, or hypopharynx [8]. HPV-positive
HNSCCs have genetic alterations that are direct result of
HPV oncoproteins, E6 and E7, which inactivate the
tumor suppressor gene products, p53 and Rb, respec-
tively. In addition, HPV-positive HNSCCs also vary in
their allelic and chromosomal stability as well as global
gene expression profiles and DNA methylation profiles
[9]. Patients with HPV-positive OPSCC have a better
prognosis and response to therapy compared to HPV-
negative patients. Loco-regional control is also signifi-
cantly better in HPV-positive OPSCC, but the rate of
distant metastasis increases after 2 years unlike in
patients with HPV-negative tumor [10]. Furthermore,
metastases are more likely to occur significantly later in
HPV-positive OPSCC compared to HPV-negative
tumors, involving multiple organs, such as the skin,
intra-abdominal lymph nodes, and brain [10]. However,
the implication of HPV status in nonoropharyngeal sites
on prognosis and distant metastasis remains unclear.
Even though HPV has now been recognized as an inde-
pendent risk factor for a subset of HNSCC, the HPV-
related oncogenic pathways that influence HNSCC biol-
ogy are still not well understood. Treatment strategies in
the future may target specific molecular pathways that
differ between HPV and non-HPV-associated HNSCC,
which highlights the importance of the accurate identifi-
cation of this distinction between the two different
HNSCC subtypes. This review summarizes the current
knowledge on the oncogenic pathways associated with
HPV and how these insights have translated into the
current regime of diagnostics for HPV-positive HNSCC.
Furthermore, novel approaches involving the use of oral
fluid and new molecular biomarkers may pave the way
for better screening and diagnostic strategies for HPV-
positive HNSCC patients.
Epidemiology of HPV-Positive OPSCC
The significant increase in HPV-associated OPSCC over
the last decade among nonsmoking, young individuals
[11] reflects an increasing prevalence of oral HPV infec-
tion as a causative factor, possibly due to changes in sexual
behavior [12, 13]. Studies have shown a varying preva-
lence of HPV infection in various population groups living
in different geographical regions, that is, 0.6% in Japan (4/
662 individuals of various ages from Miyako Island) [14],
6.9% in the United States (385/5579 individuals aged
14–69) [15], 9.3% in Sweden (45/483 individuals aged 15–
23) [16], and 2.3% in Australia (7/307 individuals aged
18–35) [13].
Most HPV infections do not progress to cancer, how-
ever, delayed clearance of infection has been shown to be
a risk factor for the development of anogenital cancer
[17, 18]. The incidence of HPV-positive OPSCC is
increasing significantly, with an estimated 22,000 cases
with HPV positivity from 85,000 OPSCC cases worldwide
in 2008 [19]. Between 1988 and 2004, there was a 225%
increase in the incidence of HPV-positive OPSCC, and a
simultaneous 50% decrease in HPV-negative OPSCC in
the United States [11] with similar trends recorded in
Europe and Australia [20, 21]. It has been estimated that
25.6% of OPSCC worldwide are HPV-related and this
may vary by geographical regions [22]. The proportion of
HPV-positive OPSCC was 56% in North America; 52%
in Japan; 45% in Australia; 39% in Northern and Western
Europe; 38% in Eastern Europe; 17% in Southern Europe;
and 13% in the rest of the world [22].
The incidence of HPV-positive OPSCC is the highest
among middle-aged, nonsmoking white males (40–
59 years old) with higher socioeconomic status and mul-
tiple sexual partners [23]. Patients with HPV-positive
OPSCC are less likely to consume tobacco and alcohol
compared to patients with HPV-negative OPSCC [12,
24]. HPV-positive OPSCC patients have on average more
than 8–10 sexual partners with a history of more than
four oral sexual partners [25–28]. Sexually acquired HPV
is generally cleared on its own but in few cases viral DNA
is integrated into the host genome, which is a key step in
HPV-induced carcinogenesis.
HPV positivity in OPSCC is associated with a reduc-
tion in the risk of death compared to patients with HPV-
negative tumors. A study has shown that patients with
HPV-positive OPSCC had a higher 5-year disease-free
survival (75% vs. 14%) and overall survival (79% vs.
19%) compared to patients with HPV-negative tumors
[29]. The more favorable outcome for patients with
HPV-positive OPSCC is associated with improved
response to chemotherapy (82% vs. 55%) and chemoradi-
ation (84% vs. 57%) compared to HPV-negative patients
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[30]. The prognostic advantage of HPV-positive OPSCC
is partly attributed to the patient population affected—
which is the younger age group, decreased tobacco con-
sumption, and a higher performance status. However, in
studies adjusted for these confounders, the improved
prognosis of HPV-positive OPSCC still persists [10], indi-
cating a fundamental biological difference between HPV-
positive and -negative diseases, which remains unclear.
HPV L1, the major capsid protein that can self-assem-
ble into virus-like particles (VLP) is the basis for HPV
vaccines that generate neutralizing antibodies against the
VLP proteins [31]. There has been strong evidence from
clinical trials supporting this argument for both the biva-
lent HPV16/18 vaccine and quadrivalent HPV 6/11/16/18
vaccine against cervical, vaginal, and vulvar infections in
women [32, 33]. The quadrivalent vaccine has also been
shown to be effective against anogenital HPV infections
in men [34, 35]. Due to the fact that oropharyngeal HPV
infection is largely associated with sexual behaviors, the
decrease in prevalence of genital HPV infection by the
vaccine might indirectly reduce the incidence of oral HPV
infection, independent of the potential direct effect of the
vaccine on oropharyngeal HPV infection. To date, there
is only one study that has assessed the effect of HPV vac-
cine against oropharyngeal HPV infections [36]. Among
patients who participated in this trial, vaccine efficacy
(VE) against oral HPV16/18 infection was 93% (1/2910
infection in vaccinated group and 15/2924 in the control
group) [36]. This study provided proof-of-principle that
HPV vaccine may prevent HPV-induced oral and oropha-
ryngeal cancers. However, the current population age
group of >30 years may not benefit from HPV vaccina-
tion because prophylactic vaccines do not clear HPV
infections.
HPV Biology and Malignant
Transformation by E6 and E7 Viral
Oncoproteins
HPV is a member of the Papillomaviridae family, small
DNA viruses that are commonly detected in various spe-
cies including birds and mammals [37]. HPVs exclusively
infect human epithelial cells and are associated with dif-
ferent anatomic site preferences for either cutaneous or
mucosal squamous epithelium [38]. High-risk (HR) HPV
types, such as HPV-16, -18, -31, and -33, are commonly
found in cervical squamous cell carcinomas [39], other
anogenital malignancies [40], and in a subset of HNSCC
[39].
The HPV genome consists of a small double-stranded
DNA of ~8000 base pairs, divided into three major
regions. The early genes (E1–E7) are expressed early in
the viral infectious cycle for the regulation of transcrip-
tion, plasmid replication, and transformation. The late
genes code for the major (L1) and minor (L2) capsid pro-
teins, involved in the packaging of viral genome and virus
release. The long control region (LCR) contains the regu-
latory elements for transcription and replication. E6 and
E7 encode the main HPV oncoproteins that promote cell
cycle progression and viral DNA replication. As most
people with HPV infection do not develop cancers,
expression of E6 and E7 is necessary but not sufficient for
malignant transformation. However, increased prolifera-
tive capacity and evasion of apoptosis induced by E6 and
E7 can lead to the accumulation of DNA damage and
mutations that can ultimately result in malignant trans-
formation and carcinogenesis.
The major role of high-risk E7 protein is to reprogram
terminally differentiated epithelial cells at the surface epi-
thelium in order for the host cells to re-enter the cell
cycle, which is required for viral DNA replication. E7
binds to the retinoblastoma (Rb, a tumor suppressor pro-
tein) and other members of the Rb family, such as p107
and p130. Proteins from the Rb family regulate the G1-S
phase transition through interaction with the E2F family
of transcription factors, which in turn control many genes
that are involved in regulating cell cycle progression, dif-
ferentiation, mitosis, and apoptosis [41]. The binding of
E7 disrupts the Rb-E2F complex, leading to the inactiva-
tion of Rb through proteasomal degradation. The release
of E2F also subsequently activates responsive genes, such
as cyclin A and cyclin E, which promotes the entry of
cells into S phase [42, 43]. E7 protein also leads to
increased induction of p16INK4a, which is routinely used
as a biomarker for HPV-associated lesions and cancers.
p16INK4a is a tumor suppressor in normal cells, but it has
been shown to be essential for the survival of HPV-posi-
tive cervical cancer cell lines [44]. This oncogenic effect
of p16 depends on the inhibition of CDK4/CDK6 in can-
cer cells where Rb is inactivated, suggesting the presence
of CDK4/6 substrates that may cause cell death when
phosphorylated in cells with inactivated Rb [44].
Aberrant cell proliferation and DNA synthesis in the
absence of sufficient growth signals as observed in differ-
entiating HPV-infected cells can trigger p53-dependent
apoptotic programs. The inactivation of Rb by E7 protein
sensitizes cells to p53-dependent apoptosis, but E6 protein
targets p53 for degradation, thus inhibiting the proapop-
totic functions of p53 [45]. E6 binds directly to E6-associ-
ated protein (E6-AP), a specific ubiquitin-ligase for p53
degradation. A study has shown that the repression of
HR E6 and E7 expression in oropharyngeal cancer cells is
associated with restoration of p53 and Rb tumor suppres-
sor pathways and increased apoptosis [46]. In addition,
E6 and E7 also interfere with growth inhibitory cytokines
released by host cells upon HPV infection, such as
ª 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 3
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tumor-necrosis factor-a (TNFa). TNFa activates the
extrinsic apoptotic pathway through TNF receptor 1
(TNFR1), FAS4 and the TNF-related apoptosis-inducing
ligand (TRAIL) receptors. E6 abrogates the apoptotic
effect of TNFa by binding to TNFR1, which inhibits the
subsequent transduction of apoptotic signals [47]. E6 can
also disrupt the mitochondrial apoptotic pathway by
interactions with the proapoptotic Bcl2 members BAK
and BAX as well as inducing the expression of inhibitors
of apoptosis proteins (IAPs) and survivin [48].
The expression of E6 and E7 can result in the immor-
talization of host cells but it is insufficient to directly
transform cells. HR E6 and E7 independently induce
genomic instability in normal cells [49], which is a neces-
sary step for malignant transformation. The expression of
E6 and E7 has been shown to result in mitotic defects,
such as multipolar mitoses, anaphase bridges, and aneu-
ploidy [50]. Under normal circumstances, cells with mito-
tic defects are targeted for cell death. Through the actions
of E6 and E7 on cell cycle checkpoints and apoptosis,
cells with abnormal centrosomes are allowed to survive
and accumulate [51, 52]. E6 and E7 can also induce DNA
damage and increase the frequency of foreign DNA inte-
gration into the host genome [53, 54]. The activation of
ATM–ATR pathway (ataxia telangiectasia-mutated—ATM
and RAD3-related DNA damage repair pathway)-depen-
dent DNA damage response is important for the replica-
tion of differentiation-dependent viral genome, but not
the stable maintenance of episomes in undifferentiated
epithelial cells [55]. Furthermore, E7 can abrogate ATM–
ATR-induced cell cycle checkpoints to promote cell cycle
progression regardless of the presence of DNA damage,
leading to genomic instability and malignant progression
[56].
Current Diagnostics for HPV-Positive
HNSCCs
Currently, there is no consensus on the optimal way to
identify HPV-positive HNSCC. Different methods include
the detection of p16 protein expression using immunohis-
tochemistry (IHC) as well as HPV-related genetic material
using polymerase chain reaction (PCR) and in situ
hybridization (ISH) in tumor biopsy samples. In addition,
the presence of HPV-specific antibodies in serum has also
been associated with increased risk of developing OPSCC
[28, 57].
p16 immunohistochemistry
During immortalization of host cells, the E7 protein of
HR-HPV binds to Rb, resulting in the compensatory
overexpression of the tumor suppressor gene p16 in
HPV-infected tumor cells [58]. The IHC analysis of
p16INK4A in HNSCC tumor biopsies has been shown to
serve as a surrogate marker to identify HPV infection in
histologic preparations from HNSCCs [59]. However, in
a pooled analysis of 496 patients with OPSCC from dif-
ferent studies utilizing DNA-based HPV testing, 5% of
cases were p16INK4A-positive/HPV-negative and 8% were
p16INK4A-negative/HPV-positive [60]. Another study has
shown that p16INK4A is also overexpressed in a subset of
HNSCC lacking HPV DNA, with close to 14% of tumors
that were p16-positive were negative by HPV-specific ISH
and PCR [61] 5. Strikingly, Hoffmann et al. reported that
no overexpression of p16INK4A was observed in 3/14
(21.4%) patients who were positive for HPV DNA and
mRNA [62]. Furthermore, Harris et al. demonstrated an
overexpression of p16 in young patients with oral tongue
SCC without evidence of HPV infections [63]. Liang et al.
also showed that OPSCC patients who were p16-positive
and seronegative for HPV antibodies had significantly
increased hazard of all causes of death [64]. These data
support the notion that p16 overexpression alone is not
sufficient to accurately identify HPV infection in HNSCC.
However, p16 IHC has been shown to be a suitable test
for risk stratifying patients with OPSCC as p16 positivity
in tumor correlates with better survival [65]. p16 IHC has
been adopted as a single test of choice for many medical
practitioners due to the fact that it has been extensively
studied and cost effective with clear staining interpreta-
tion guidelines [65]. Direct identification of HPV using
DNA and RNA-based methods will still be required for
clinically relevant infection and may replace p16 IHC or
used in conjunction with it in the future [65].
HPV DNA detection
PCR is a highly sensitive and cost-effective method for
the detection of HPV. Due to the high number of HPV
strains, primers targeting the conserved L1 open reading
frame are commonly used to detect a broad spectrum of
HPV, such as the MY09/MY11 and GP5/GP6 primer pairs
[66, 67]. The MY09/MY11 primer pair is synthesized with
several degenerate nucleotides in each primer and is thus
a mixture of 25 primers capable of amplifying a wide
spectrum of HPV types [68]. In contrast, there are only
two primers, GP5/GP6 and the detection of multiple
HPV strains is achieved by lowering annealing tempera-
ture during PCR [68]. Due to the use of consensus
sequences of L1 from multiple subtypes, specific genotyp-
ing is not possible with MY09/MY11 and GP5/GP6 pri-
mer pairs. Moreover, the L1 region of the HPV genome
may be deleted upon viral integration into the host gen-
ome, hence decreasing the sensitivity of HPV detection.
PCR strategy targeting the tumorigenic E6 and/or E7
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sequence, which is retained by infected cells through viral
genome integration, may prove to be more sensitive in
the detection of HPV. This was highlighted by a study of
HPV detection in anal carcinoma that showed a lower
detection rate with L1 consensus primers (16%), whereas
strain-specific E6 primers yielded a HPV positivity of
46% [69].
E6 and E7 regions have been shown to harbor many
sequence variations between HPV types [70]. Suitable
primers directed toward E6/E7 of different HPV strains
can be designed to not only determine if HPV is present
but also—at the same time—to distinguish between HR
and low-risk strains. However, standard PCR techniques
have low specificity and do not allow for a distinction
between tumor-derived or healthy stroma-derived HPV.
Furthermore, PCR techniques are not able to distinguish
between episomal and integrated HPV DNA, thus
decreasing the ability to detect clinically relevant infec-
tion. Currently, there are no standardized PCR-based
methods in clinical application, leading to varied analyti-
cal sensitivities and specificities of PCR-based assays
between laboratories. However, studies have shown that
when used in conjunction with a standardized protocol
and quality-controlled reagents, PCR-based HPV detec-
tion methods demonstrated good interlaboratory agree-
ment [71].
Another method of HPV DNA detection in tumor
samples is ISH. The advantage of ISH over a PCR method
is the high specificity due to the reliable detection and
identification of HPV in topographical relationship with
their pathological lesions [72]. The result of ISH can be
evaluated microscopically and the appearance of precipi-
tate within the nuclei of epithelial cells is indicative of
HPV presence [72]. Furthermore, integrated and episomal
HPV DNA can be distinguished by the presence of punc-
tate or diffuse signals, respectively [72]. As discussed in
the previous section, HPV DNA presence as detected by
ISH was significantly correlated with p16 IHC [73]. In
spite of the high specificity of this method (100%), the
sensitivity is low (86%) with an estimated 13–41% false-
negative rate in HNSCC [74, 75].
HPV RNA detection
The expression of mRNA from integrated and episomal
HPV DNA indicates that viral oncogenic transcripts are
crucial in tumor initiation and progression [76]. There-
fore, PCR methods targeting HPV mRNA is a better
approach than DNA-based methods in providing evidence
of clinically relevant HPV infection. A study by Deng
et al. showed that E6/E7 transcripts were detected only in
15/54 (27.5%) of the HPV-positive tumor samples, which
also correlated with high HPV16 DNA load [77]. Another
study by Holzinger et al. showed that E6/E7 transcripts
were detected in 48/96 (50%) OPSCC tumor samples
tested positive for HPV DNA [78]. Consistent with the
findings of Deng et al., Holzinger et al. showed a signifi-
cant positive correlation between high viral load and E6/
E7 mRNA expression levels. Moreover, E6/E7 mRNA
expression has been shown to be highly expressed in
HPV-infected tonsillar SCC (75%) and lower expression
was observed in other oropharyngeal areas [77]. This
might indicate that E6/E7 mRNA expression is more pre-
valent in tonsillar carcinomas. Due to the instability of
RNA and the suboptimal preservation of routine biopsy
samples using formalin-fixed paraffin-embedded (FFPE)
analyses, the methods discussed thus far for HPV tran-
script detection rely on the analysis of fresh-frozen tissue
in research laboratories, therefore hampering the transla-
tion to routine clinical diagnostic. More recently, HR
HPV E6/E7 mRNA ISH has been developed as a potential
detection tool in FFPE tissues. In a study of 196 OPSCC
patients, RNA ISH was positive in 147/148 (99.3%) of the
p16-positive tumors, and demonstrated a better sensitivity
in HPV detection than DNA ISH [79]. Concordantly,
Schache et al. reported sensitivity and specificity of 97%
and 93%, respectively, in the detection of HR-HPV using
RNA ISH in FFPE OPSCC samples [80]. These data dem-
onstrated that the detection of HPV transcripts is highly
concordant with active and clinically relevant HPV infec-
tion, which can be incorporated into current clinical diag-
nostics.
The specificity of HPV-specific DNA and RNA ISH for
HPV infection in tumor samples in combination with the
high sensitivity of p16 IHC or HPV DNA PCR can be an
effective diagnostic strategy for HPV-associated HNSCC.
It has been suggested that screening tumors with p16
IHC to be performed first, and upon positive result, to
be followed by HPV-specific test, such as ISH or PCR
[73, 81]. This will provide evidence that HPV is in the
tumor and that the HPV is transcriptionally active based
on p16 overexpression and E6/E7 mRNA expression lev-
els [65].
HPV serology
The detection of HPV-specific IgG in serum is a useful
biomarker to determine previous and current HPV infec-
tion status [82]. Serological biomarkers are not site-spe-
cific, and can arise due to HPV infections at sites other
than the oral cavity, hence potentially affecting the speci-
ficity of the assay. However, an earlier study involving
900,000 subjects has shown a significant association
between the presence of oncogenic HPV-specific antibod-
ies and an increased risk of HNSCC [57]. An earlier study
by Cameron et al. showed that the presence of HPV-spe-
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cific immunoglobulin G (IgG) in serum and saliva was
observed in HIV-positive individuals with elevated risk
for HPV infections [83]. A more recent study has shown
a strong correlation between HPV16 E1, E2, and E7 anti-
body levels in OPSCC patients compared to healthy con-
trols [84]. Furthermore, OPSCC patients with HPV16 E6
and E7 seropositivity also showed a more favorable all-
cause survival compared to seronegative patients [64].
Collectively, seropositivity of HPV-specific antibodies is a
potential surrogate marker and prognostic marker for
HPV-associated OPSCC.
HPV detection in oral fluid
Most of the current diagnostic assays are designed for
excised tumor tissues obtained at the time of surgical
biopsy or resection. More recently, the use of biological
markers in oral fluids for the detection of HPV-associated
HNSCC has been gathering a lot of attention due to the
noninvasive and cost-effective nature, as well as the prox-
imity to oral tumors, which allows for early cancer detec-
tion and monitoring of disease progression [85]. Oral
fluid has been shown to contain different analytes, such
as hormones, steroids, antibodies, growth factors, cyto-
kines, chemokines, and drugs, that may reflect local and
systemic disease states [86–88]. It also contains whole
cells, genetic materials, as well as proteins that may allow
for the detection of HPV and cellular alterations in
infected cells, which may aid in early detection and HPV-
typing of HNSCC tumors. Recent studies on the detection
of HPV in oral fluid for the diagnosis of HNSCC are out-
lined and summarized in Table 1.
An earlier study of oral exfoliated cells and tumor tis-
sues from HNSCC patients (n = 201) revealed that there
was a significant correlation between HR-HPV detected
in oral rinse and the HR-HPV types present in tumor tis-
sues [89]. The data suggest that an assessment of HPV
genotypes in oral rinse maybe predictive of HPV-associ-
ated HNSCC, and have shown that HPV infection is a
risk factor for HNSCC independent of alcohol and
tobacco use. Compared to the use of swabs or scrapes to
collect mucosal cells from a limited number of oral sites,
the use of oral rinse is likely to have sampled the tumor
site and the localized field of HPV infection [89]. Another
study utilized real-time quantitative PCR (RT-qPCR) to
detect HPV16 E6 and E7 DNA in oral rinses as a screen-
ing method for HNSCC [90]. RT-qPCR enables a more
accurate quantification of HPV DNA copy number pres-
ent in samples and hence an improved sensitivity for
HPV detection compared to nonquantitative amplifica-
tion methods. A total of 42/92 (45.7%) primary tumor
tissues and 30/92 (32.6%) oral rinses from HNSCC
patients had detectable HPV16 DNA.
HPV DNA detection in tumor tissue and oral rinse
from patients with tumors demonstrated a significant cor-
relation (P < 0.001). However, the authors noted that
some tumors that were HPV-positive did not yield HPV
positivity in the oral rinses, and that the oral rinse level
of HPV16 was significantly lower than that of the tumor,
presumably due to the diluting effect of normal exfoliated
cells unrelated to the tumor cells [90].
Chuang et al. examined HNSCC tumors and paired
pre- and posttreatment oral rinse samples from 59
patients for HPV16 using RT-qPCR for the diagnosis of
persistent and recurrent HNSCC [91]. Before treatment,
20/59 (33.9%) patients were HPV16-positive in their
tumors. After treatment, 4/20 (20%) of these patients
ultimately developed recurrence and 2/4 (50%) were
HPV16-positive in surveillance oral rinses, with an assay
sensitivity and specificity for recurrence based on HPV
positivity of 50% and 100%, respectively, albeit with a
small sample size. Another study has found no association
between oral HPV infection after therapy and tumor
recurrence, due to the fact that the majority of the HPV
infection detected in oral rinse after therapy was not iden-
tical to that found in tumor [92]. However, a recent pro-
spective study demonstrated that HPV detection in oral
rinse was comparable to that of HPV presence in tumor
tissues [93]. In addition, the presence of antibodies spe-
cific to viral oncoproteins in sera was found to be corre-
lated with favorable prognosis and lower frequency of
recurrence [93]. This was consistent with an earlier study
that showed the presence of HPV DNA in tumor tissues
and in oral rinse samples and was associated with the
presence of HPV-specific antibodies in sera [94]. Despite
the low assay sensitivity for tumor recurrence due to the
low sampling size of the studies, these data have exhibited
the feasibility of correlating HR HPV DNA positivity in
oral rinses and HPV-related antibodies in blood for the
detection and surveillance of disease progression.
A study by Fakhry et al. aimed to develop a cytology
test for the detection of HPV-associated HNSCC from
populations with elevated risk of developing OPSCC,
namely patients with abnormal oropharyngeal lesions and
HIV-infected patients [95]. Using a PCR-based method
with consensus MY09/MY11 and HPV16-specific primers,
the authors have found that HPV16 was present in tonsil-
lar brushings and oral rinses in 48/91 (52.7%) patients
with abnormal oropharyngeal lesions and in 72/1524
(4.7%) specimens from HIV-infected patients (n = 401)
without such lesions. Another study also included the HR
group of HIV-positive patients and found that HPV DNA
was detected in saliva of 7/68 (10.3%) of oral cancer
patients and in 12/34 (35.3%) HIV-positive individuals
[96]. The presence of HR-HPV DNA in oral samples may
therefore be a strong biomarker for the development of
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OPSCC in HR groups with premalignant lesions and
immuno-compromised individuals.
A recent study analyzed and correlated the presence of
HPV DNA in oral samples (oral rinses and/or tonsillar
swabs) in patients with the incidence of HPV-positive
tonsillar and base of tongue cancer [97]. The presence of
HPV DNA in oral samples that is concordant with HPV
positivity in tumor samples was detected in 18/22 (76%)
and 8/16 (50%) of patients with tonsillar and base of
tongue cancer, respectively. This is consistent with the
fact that the majority of HPV-positive HNSCC is found
in the tonsillar and base of tongue regions [98, 99], dem-
onstrating the site specificity of HPV detection in oral
rinse.
Studies to date have collectively demonstrated promis-
ing data for the utilization of oral fluid as a valid speci-
men for the detection of HR HPV as well as other
prognostic markers. Currently, there is only one labora-
Table 1. Recent studies on the detection of HPV in oral fluid of HNSCC patients.
Study Tumor HPV DNA Saliva HPV DNA Detection method Summary of findings
Smith et al. [23, 89] 38/190 (20%) 57/190 (28.4%) PCR of L1 HR-HPV in oral rinse is a risk factor for HNSCC
independent of alcohol and tobacco consumption
Zhao et al. [90] 28/92 (30.4%) 16/92 (17.4%) RT-qPCR of
HPV16 E6 and E7
Quantitative analysis of HR-HPV DNA allows for
the detection of HPV-associated HNSCC, but is
not predictive of HNSCC in general
Chuang et al. [91] 20/59 (33.9%)
pretreatment
2/20 (10%)
posttreatment
RT-qPCR of
HPV16 E6 and E7
Patients with HR-HPV DNA in oral rinse
posttreatment are at significant risk for tumor
recurrence. Small sample size
Agrawal et al. [92] 44/135 (32.6%)
pretreatment
30/133 (22.6%)
pretreatment,
37/135 (27.4%)
posttreatment
PCR of L1
and hybridization
to a linear
probe array
HR-HPV DNA were more likely to be present in
oral rinse of HPV+ than HPV HNSCC patients
before and after therapy but is not a prognostic
marker for recurrence
Adamopoulou
et al. [96]
Not performed 7/68 (10.3%) in
oral cancer,
12/34 (35.3%)
in HIV+
PCR of L1 and
genotyping
by RFLP
The detection rate of HPV in saliva is higher in
HIV+ individuals than patients with oral cancer
Tachezy et al. [94] 53/86 (61.6%) 37/86 (43%) PCR of L1 and
genotyping
reverse line
blot
hybridization (RLB)
The presence of HPV DNA in oral rinse is
significantly correlated with the presence of
HPV DNA in tumor and HPV-specific
antibodies in sera
Fakhry et al. [95] Not performed 48/91 (52.7%)
precancerous
lesions, 72/1524
(4.7%) from
multiple
follow-ups
in 401
HIV+ individuals
PCR of L1
and HPV16 E6
The combination of HPV16 and abnormal
cytology detected in oral samples (tonsillar
brush and oral rinse) of patients with precursor
lesions, but not HIV+ individuals, was
associated with OSCCs
Koslabova et al. [93] 83/141 (58.9%) 64/83 (77.1%)
pretreatment,
63/83 (75.9%)
posttreatment
PCR of L1
and sequencing
HPV DNA presence in oral rinse and the presence
of HPV-specific antibodies correlate with HPV
infection in tumor tissues, but HPV presence
cleared up in oral rinse 1 year posttreatment.
Sustained seropositivity for HPV16 oncoproteins
posttreatment is a more specific marker
for recurrence
Nordfors et al. [97] 22/29 (75.9%)
tonsillar carcinoma,
16/18 (88.9%) base
of tongue carcinoma
18/29 (62.1%)
tonsillar
carcinoma,
8/18 (44.4%)
base of tongue
carcinoma
PCR of L1
and HPV16 E6;
Bead-based
multiplex assay
for HPV
genotyping
The presence of HPV DNA in oral samples is
significantly correlated with HPV-positive
tumors in the tonsillar and base of tongue region
HR-HPV, high-risk human papilloma virus; RT-qPCR, real-time quantitative polymerase chain reaction; HNSCC, head and neck squamous cell carci-
noma.
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tory-based salivary diagnostic test available to detect HPV
(OraRisk HPV test; OralDNA Labs6 ) that determines the
risk of developing HPV infection by detecting different
strains of HPV such as HPV8, 11, 16, and 18 via PCR
using oral rinse samples. However, the clinical perfor-
mance interims of the sensitivity and specificity of this
test and other oral fluid-based detection methods lack
experimental evidence. It is also important to experimen-
tally validate if HPV infection is current/active or in the
past. Oral fluid based tests to determine HPV infection
require further improvements due to the different origins
of the cells being tested in oral fluid, namely HPV-posi-
tive tumor cells, any associated HR-HPV infection that
can lead to the development of oral cancers or an inde-
pendent HR HPV infection, as well as the percentage of
host healthy exfoliated cells and immune cells [72].
Conclusions
HPV-associated HNSCC represents a distinct entity from
tobacco and alcohol-related HNSCC. The expression of
HR-HPV oncoproteins E6 and E7 upon viral infection
and integration results in the immortalization of host cells
and subsequent malignant transformation through
increased proliferative capacity, upregulation of antiapop-
totic pathways and increased genomic instability. Cur-
rently, the treatment plans for nonoropharyngeal HNSCC
patients do not change with respect to HPV status.
However, the improved outcome in patients with HPV-
positive OPSCC has been shown in many studies and the
de-escalation of treatment for this subset of HNSCC has
been proposed [100], further highlighting the importance
of HPV testing. The presence of HR-HPV DNA and
HPV-associated protein markers in tumor biopsy are cur-
rently being utilized to diagnose HPV-positive HNSCC.
Oral fluid presents a promising noninvasive alternative
for the detection of oncogenic HPV DNA that correlates
significantly with HPV infection in tumors in recent stud-
ies. However, further development and validation of HPV
detection in oral fluid is warranted due to the low sensi-
tivity and specificity for clinically relevant HPV infection
before being implemented as a clinical diagnostic med-
ium. The incorporation of novel screening methods into
the current diagnostic regime will enable the early detec-
tion and intervention, risk assessment, and response to
treatment of HNSCC.
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The current review summarizes the epidemiology of human papilloma virus (HPV)-related head and neck squamous cell
carcinoma (HNSCC) and the disease burden, the infectious cycle of HPV, the roles of viral oncoproteins, E6 and E7, and
the downstream cellular events that lead to malignant transformation. We also reviewed the current regimes and novel
noninvasive methods of HPV detection.
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